Literature DB >> 13367341

Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy.

R M MCCUNE, R TOMPSETT.   

Abstract

Observations are presented on the behavior of populations of tubercle bacilli in the tissues of mice during the administration of antimicrobial drugs. The behavior of the populations during therapy with any particular drug was different depending upon whether the tubercle bacilli were subsisting in the lung or in the spleen. Moreover, the pattern of microbial behavior was distinctive and predictable for each drug studied. Changes in the size of the populations of tubercle bacilli in the tissues appeared to be a more sensitive reflection of drug influence than microscopic study of the number and character of the tuberculous lesions. Nevertheless, in untreated animals, pulmonary lesions evolved and progressed steadily to a fatal outcome despite the fact that the populations of tubercle bacilli had stabilized at a relatively high census early in the course of therapy. The uniform persistence of tubercle bacilli in the spleen throughout prolonged drug administration was demonstrated with every drug or multiple drug regimens except for pyrazinamide when accompanied by isoniazid. Cultures of the bacilli which survived in the tissues despite antimicrobial therapy were highly susceptible to the drugs employed when tested in vitro. Thus the survival of the tubercle bacilli in the tissues represented microbial persistence rather than drug resistance. When pyrazinamide and isoniazid were administered together, it was not possible to detect the microorganisms in the spleen or lungs of treated animals. A detailed investigation of this apparent abolition of microbial persistence forms the subject of an accompanying report.

Entities:  

Keywords:  ISONIAZID/effects; NICOTINIC ACID/related compounds; PARA-AMINOSALICYLIC ACID/effects; STREPTOMYCIN/effects; TUBERCULOSIS/experimental

Mesh:

Substances:

Year:  1956        PMID: 13367341      PMCID: PMC2136613          DOI: 10.1084/jem.104.5.737

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  5 in total

1.  The influence of pyrazinamide-isoniazid on M. tuberculosis in animals and man.

Authors:  R TOMPSETT; R M McCUNE; L ORMOND; K DEUSCHLE; C MUSCHENHEIM; W McDERMOTT
Journal:  Trans Assoc Am Physicians       Date:  1954

2.  Pyrazinamide-isoniazid in tuberculosis.

Authors:  W McDERMOTT; L ORMOND; C MUSCHENHEIM; K DEUSCHLE; R M McCUNE; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-03

3.  Nonautomatic pipetting devices for the microbiologic laboratory.

Authors:  A G WEDUM
Journal:  J Lab Clin Med       Date:  1950-04

4.  Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis.

Authors:  R L YEAGER; W G C MUNROE; F I DESSAU
Journal:  Am Rev Tuberc       Date:  1952-05

5.  The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug.

Authors:  R M MCCUNE; W MCDERMOTT; R TOMPSETT
Journal:  J Exp Med       Date:  1956-11-01       Impact factor: 14.307

  5 in total
  89 in total

1.  Metronidazole therapy in mice infected with tuberculosis.

Authors:  J V Brooks; S K Furney; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Veronica Gruppo; Lisa K Woolhiser; Ian M Orme; Janet C Gilliland; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

3.  An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis.

Authors:  Toshiko Miyata; Chan-Ick Cheigh; Nicola Casali; Amador Goodridge; Olivera Marjanovic; Lon V Kendall; Lee W Riley
Journal:  Vaccine       Date:  2011-11-08       Impact factor: 3.641

4.  Bacterial population studies in chronic murine tuberculosis.

Authors:  R J REES
Journal:  Proc R Soc Med       Date:  1961-07

5.  Cellular immunity.

Authors:  S S ELBERG
Journal:  Bacteriol Rev       Date:  1960-03

6.  [Mechanisms of nonspecific infection resistance].

Authors:  D BOHME
Journal:  Klin Wochenschr       Date:  1958-09-15

7.  Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals.

Authors:  Sarah Schmidt Grant; Benjamin B Kaufmann; Nikhilesh S Chand; Nathan Haseley; Deborah T Hung
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

Review 8.  Bacterial persistence: some new insights into an old phenomenon.

Authors:  R Jayaraman
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

9.  Lysostaphin in experimental renal infections.

Authors:  E F Harrison; W A Zygmunt
Journal:  J Bacteriol       Date:  1967-02       Impact factor: 3.490

10.  Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.

Authors:  John D Szumowski; Kristin N Adams; Paul H Edelstein; Lalita Ramakrishnan
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.